| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$43.1M | ROE | −203.63% |
| Net Margin | — | ROIC | — |
| Debt / Equity | 0.00 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $12.9M | Trading Days | 1270 |
| 52W High | 12.22 |
| 52W Low | 0.87 |
| % Off High | −92.87% |
| YTD | −69.65% | 1Y | −89.22% |
| 3Y | −93.29% | 5Y | −99.56% |
| Since incept. (ann.) | −64.25% |
| Ann. Volatility (1Y) | 102.82% | Ann. Volatility (3Y) | 2309.69% |
| Sharpe (1Y) | −1.64 | Sharpe (3Y) | 0.52 |
| Max Drawdown (1Y) | −92.64% | Max Drawdown (3Y) | −99.31% |
| Beta (3Y, vs SPY) | −6.74 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| COCP | Cocrystal Pharma, Inc. | $12.9M | — |
| LEXX | Lexaria Bioscience Corp. | $13.4M | — |
| ANEB | Anebulo Pharmaceuticals, Inc. | $13.5M | — |
| CTXR | Citius Pharmaceuticals, Inc. | $13.7M | — |
| HIND | Vyome Holdings, Inc | $14.0M | — |
| PHIO | Phio Pharmaceuticals Corp. | $11.7M | — |
| BFRI | Biofrontera Inc. | $14.2M | — |
| MBRX | Moleculin Biotech, Inc. | $11.7M | — |
| GTBP | GT Biopharma, Inc. | $11.4M | — |
| KPRX | KIORA PHARMACEUTICALS INC | $11.4M | — |
| CALC | CalciMedica, Inc. |
| $11.3M |
| — |
| XCUR | EXICURE, INC. | $11.1M | — |
